Amplitude Vascular's New Funding Round Shows Why the IVL Market Is Red HotAmplitude Vascular's New Funding Round Shows Why the IVL Market Is Red Hot

Amplitude Vascular Systems has raised $36 million to help fund the launch of its intravascular lithotripsy. The Boston, MA-based company is in a highly competitive market where Johnson & Johnson and Boston Scientific hold significant market share.

Omar Ford

January 28, 2025

2 Min Read
designer491 via iStock / Getty Images

A player in the intravascular lithotripsy (IVL) space has reached a significant milestone.

Amplitude Vascular Systems said it has closed on a series B round financing of $36 million. The Boston, MA-based company is using the funding to support the peripheral commercial launch as well as the coronary and carotid IDE trials for its Pulse Intravascular Lithotripsy (PIVL) device.

“We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, board chairman for AVS. “Intravascular lithotripsy now represents a large and well-proven therapy that demands new solutions for patients with severely calcified arterial disease. This investor confidence reflects the accelerated execution of critical company milestones in 2024, including the initiation of our U.S. peripheral IDE. The commitment from our partners at BioStar Capital and Cue Growth Partners reinforces the great progress toward commercial approval with this technology in the IVL space.”

AVS began enrolling patients in October 2024 in the POWER PAD II U.S. IDE trial, which is a prospective, single-arm, multi-center study evaluating the technical and clinical success of the PULSE IVL System for treating patients with calcific femoropopliteal arteries. The study will enroll up to 120 patients at 20 U.S. sites and enrollment is expected to be completed mid-year 2025.

Related:Cardiovascular Surgeon Aims to Make Type A Aortic Dissections Safer, Easier & More Affordable for Hospitals

The funding will also support the company’s coronary U.S. IDE study.

Lastly, the capital raised will support the U.S. carotid IDE trial, as part of its partnership with the Jacobs Institute in Buffalo, NY.

Observing Big Moments in IVL Market

The IVL market is projected to have a compound annual growth rate of 9.3% from 2020 to 2030, according to a report from iData Research.

There has been significant movement in the space in recent months. Johnson & Johnson made medtech headlines when it acquired Shockwave Medical for %13.1 billion, an established heavyweight in IVL.

Not to be left behind, Boston Scientific acquired Bolt, the developer of the Bolt IVL system. The acquisitions put Johnson & Johnson and Boston Scientific in a showdown in the IVL market.

Even smaller players in the space have been making traction.

Earlier this month, FastWave Medical, a company developing a laser IVL technology, reported it was awarded its 7th patent.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like